RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics price target lowered to $3 from $5 at Maxim
- Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing
- Oncolytics Biotech Advances Cancer Trials with Promising Results
- Oncolytics Biotech’s Earnings Call: Clinical Progress Amid Challenges
- Oncolytics reports Q4 EPS (10c) vs. (5c) last year